个人中心 - 老虎社区

nick name

IP属地：未知

帖子 · 3帖子 · 3
关注 · 0关注 · 0
粉丝 · 0粉丝 · 0

- nick namenick name
  ·2021-12-23
  $Allakos Inc.(ALLK)$is the company still operating ? overreact !
  1,623 评论
  点赞
  分享
  举报
- nick namenick name
  ·2021-12-23
  overreact..
  Allakos slumps 87%, draws analysts downgrade on 'disappointing' lirentelimab data<blockquote>Allakos股价暴跌87%，分析师因lirentelimab数据“令人失望”而下调评级</blockquote>
  Allakos continues to slide, falls 87.4% premarket following yesterday's announcement that its late-s
  Allakos slumps 87%, draws analysts downgrade on 'disappointing' lirentelimab data<blockquote>Allakos股价暴跌87%，分析师因lirentelimab数据“令人失望”而下调评级</blockquote>
  3,057 评论
  1
  分享
  举报
- nick namenick name
  ·2021-12-10
  reason ?
  非常抱歉，此主贴已删除
  2,816 2
  5
  分享
  举报
暂无关注

热议股票

{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"4098850726603110","uuid":"4098850726603110","gmtCreate":1635747660071,"gmtModify":1635747660071,"name":"nick name","pinyin":"nicknamenickname","introduction":"","introductionEn":"","signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":1,"headSize":2,"tweetSize":3,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"228c86a078844d74991fff2b7ab2428d-3","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资合伙人虎","description":"证券账户累计交易金额达到100万美元","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.04.03","exceedPercentage":"93.64%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"35ec162348d5460f88c959321e554969-3","templateUuid":"35ec162348d5460f88c959321e554969","name":"传说交易员","description":"证券或期货账户累计交易次数达到300次","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.04.03","exceedPercentage":"93.07%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.24","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.24","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":12,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":691219244,"gmtCreate":1640194155945,"gmtModify":1640194156071,"author":{"id":"4098850726603110","authorId":"4098850726603110","name":"nick name","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4098850726603110","authorIdStr":"4098850726603110"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/ALLK\">$Allakos Inc.(ALLK)$</a>is the company still operating ? overreact !","listText":"<a href=\"https://laohu8.com/S/ALLK\">$Allakos Inc.(ALLK)$</a>is the company still operating ? overreact !","text":"$Allakos Inc.(ALLK)$is the company still operating ? overreact !","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691219244","isVote":1,"tweetType":1,"viewCount":1623,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691210616,"gmtCreate":1640193889962,"gmtModify":1640193889962,"author":{"id":"4098850726603110","authorId":"4098850726603110","name":"nick name","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4098850726603110","authorIdStr":"4098850726603110"},"themes":[],"htmlText":"overreact..","listText":"overreact..","text":"overreact..","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691210616","repostId":"1163953446","repostType":2,"repost":{"id":"1163953446","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1640182473,"share":"https://www.laohu8.com/m/news/1163953446?lang=zh_CN&edition=full","pubTime":"2021-12-22 22:14","market":"us","language":"en","title":"Allakos slumps 87%, draws analysts downgrade on 'disappointing' lirentelimab data<blockquote>Allakos股价暴跌87%，分析师因lirentelimab数据“令人失望”而下调评级</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1163953446","media":"Tiger Newspress","summary":"Allakos continues to slide, falls 87.4% premarket following yesterday's announcement that its late-s","content":"<p>Allakos&nbsp;continues to slide,&nbsp;falls 87.4% premarket&nbsp;following yesterday's announcement that its late-stage studies, KRYPTOS and ENIGMA 2failed to achieve statistical significance.</p><p><blockquote>Allakos昨天宣布其后期研究KRYPTOS和Enigma 2未能达到统计显著性，盘前下跌87.4%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/961eae374dfe4dd479394caaf470012c\" tg-width=\"714\" tg-height=\"590\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p> The studies met their histologic co-primary endpoints but failed to achieve symptomatic endpoints.</p><p><blockquote>这些研究达到了其组织学共同主要终点，但未能达到症状终点。</blockquote></p><p> In ENIGMA, patients treated with lirentelimab achieved a 10.0-point reduction in Total Symptom Score-6 (TSS-6) at weeks 23-24 from baseline (baseline = 29.5) compared to an 11.5-point reduction in the placebo group (baseline = 27.7; p=0.343).</p><p><blockquote>在ENIGMA中，接受lirentelimab治疗的患者在第23-24周的总症状评分-6（TSS-6）较基线降低了10.0分（基线=29.5），而安慰剂组降低了11.5分（基线=27.7；p=0.343）。</blockquote></p><p> On the second co-primary endpoint of absolute mean change in patient reported Dysphagia Symptom Questionnaire in KRYPTOS trial, the high-dose group achieved a 17.4-point reduction, the low-dose group achieved an 11.9-point reduction and placebo achieved a 14.6-point reduction.</p><p><blockquote>在KRYPTOS试验中患者报告的吞咽困难症状问卷的绝对平均变化的第二个共同主要终点上，高剂量组实现了17.4分的降低，低剂量组实现了11.9分的降低，安慰剂实现了14.6分的降低。</blockquote></p><p> Following this disappointing result, several analysts lowered their ratings of the stock and slashed the price targets.</p><p><blockquote>在这一令人失望的结果之后，几位分析师下调了该股的评级并大幅下调了目标价。</blockquote></p><p> William Blair downgraded the stock to Market Perform from Outperform.</p><p><blockquote>威廉·布莱尔将该股评级从跑赢大盘下调至与大盘持平。</blockquote></p><p> Analysts of the firm say, \"while we believe lirentelimab has shown clear evidence of histologic activity against eosinophils and mast cells, the failure to achieve co-primary endpoints of patient reported symptoms in both studies raises questions about whether these histologic improvements can translate into clinical improvements.\"</p><p><blockquote>该公司的分析师表示，“虽然我们相信lirentelimab已显示出针对嗜酸性粒细胞和肥大细胞的组织学活性的明确证据，但两项研究均未能达到患者报告症状的共同主要终点，引发了这些组织学改善是否可以转化为临床改善的问题。”</blockquote></p><p> With lirentelimab performing worse than placebo, there are clearly questions as to why the clean results in Phase II didn’t translate, the analyst notes.</p><p><blockquote>分析师指出，由于利伦替利单抗的表现比安慰剂差，因此显然存在疑问，为什么II期的干净结果没有转化。</blockquote></p><p> Cowen analyst Joseph Thome has also cut the recommendation on Allakos to Market Perform from Outperform without the price target (PT) pending pipeline clarity.</p><p><blockquote>Cowen分析师Joseph Thome也将Allakos的评级从跑赢大盘下调至大盘表现，但价格目标(PT)有待管道明确。</blockquote></p><p> SVB Leerink analyst Thomas Smith downgraded the stock to Market Perform from Outperform, with PT of $17.</p><p><blockquote>SVB Leerink分析师Thomas Smith将该股评级从跑赢大盘下调至与大盘持平，PT为17美元。</blockquote></p><p> Barclays analyst Carter Gould lowered the firm's PT on Allakos to $8 from $36 and keeps an Underweight rating. The company's lead asset failed in key Phase 3 studies, Gould tells investors in a research note. He views this as the \"end game\" for lirentelimab.</p><p><blockquote>Barclays分析师Carter Gould将该公司对Allakos的PT从36美元下调至8美元，并维持跑输大盘评级。古尔德在一份研究报告中告诉投资者，该公司的主要资产在关键的第三阶段研究中失败了。他认为这是利伦替利单抗的“终结游戏”。</blockquote></p><p> Morgan Stanley says Allakos' disappointing data increase&nbsp;eosinophilic gastrointestinal diseases (EGIDs) uncertainty.</p><p><blockquote>摩根士丹利表示，Allakos令人失望的数据增加了嗜酸性胃肠道疾病（EGIDs）的不确定性。</blockquote></p><p> Jefferies analyst Maury Raycroft cut the recommendation on&nbsp;Allakos&nbsp;to Hold from Buy.</p><p><blockquote>杰富瑞(Jefferies)分析师莫里·雷克罗夫特(Maury Raycroft)将Allakos的评级从买入下调至持有。</blockquote></p><p> LifeSci Capital analyst Samuel Slutsky downgraded the stock to Market Perform from Outperform.</p><p><blockquote>LifeSci Capital分析师Samuel Slutsky将该股评级从跑赢大盘下调至与大盘持平。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Allakos slumps 87%, draws analysts downgrade on 'disappointing' lirentelimab data<blockquote>Allakos股价暴跌87%，分析师因lirentelimab数据“令人失望”而下调评级</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAllakos slumps 87%, draws analysts downgrade on 'disappointing' lirentelimab data<blockquote>Allakos股价暴跌87%，分析师因lirentelimab数据“令人失望”而下调评级</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-12-22 22:14</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Allakos&nbsp;continues to slide,&nbsp;falls 87.4% premarket&nbsp;following yesterday's announcement that its late-stage studies, KRYPTOS and ENIGMA 2failed to achieve statistical significance.</p><p><blockquote>Allakos昨天宣布其后期研究KRYPTOS和Enigma 2未能达到统计显著性，盘前下跌87.4%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/961eae374dfe4dd479394caaf470012c\" tg-width=\"714\" tg-height=\"590\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p> The studies met their histologic co-primary endpoints but failed to achieve symptomatic endpoints.</p><p><blockquote>这些研究达到了其组织学共同主要终点，但未能达到症状终点。</blockquote></p><p> In ENIGMA, patients treated with lirentelimab achieved a 10.0-point reduction in Total Symptom Score-6 (TSS-6) at weeks 23-24 from baseline (baseline = 29.5) compared to an 11.5-point reduction in the placebo group (baseline = 27.7; p=0.343).</p><p><blockquote>在ENIGMA中，接受lirentelimab治疗的患者在第23-24周的总症状评分-6（TSS-6）较基线降低了10.0分（基线=29.5），而安慰剂组降低了11.5分（基线=27.7；p=0.343）。</blockquote></p><p> On the second co-primary endpoint of absolute mean change in patient reported Dysphagia Symptom Questionnaire in KRYPTOS trial, the high-dose group achieved a 17.4-point reduction, the low-dose group achieved an 11.9-point reduction and placebo achieved a 14.6-point reduction.</p><p><blockquote>在KRYPTOS试验中患者报告的吞咽困难症状问卷的绝对平均变化的第二个共同主要终点上，高剂量组实现了17.4分的降低，低剂量组实现了11.9分的降低，安慰剂实现了14.6分的降低。</blockquote></p><p> Following this disappointing result, several analysts lowered their ratings of the stock and slashed the price targets.</p><p><blockquote>在这一令人失望的结果之后，几位分析师下调了该股的评级并大幅下调了目标价。</blockquote></p><p> William Blair downgraded the stock to Market Perform from Outperform.</p><p><blockquote>威廉·布莱尔将该股评级从跑赢大盘下调至与大盘持平。</blockquote></p><p> Analysts of the firm say, \"while we believe lirentelimab has shown clear evidence of histologic activity against eosinophils and mast cells, the failure to achieve co-primary endpoints of patient reported symptoms in both studies raises questions about whether these histologic improvements can translate into clinical improvements.\"</p><p><blockquote>该公司的分析师表示，“虽然我们相信lirentelimab已显示出针对嗜酸性粒细胞和肥大细胞的组织学活性的明确证据，但两项研究均未能达到患者报告症状的共同主要终点，引发了这些组织学改善是否可以转化为临床改善的问题。”</blockquote></p><p> With lirentelimab performing worse than placebo, there are clearly questions as to why the clean results in Phase II didn’t translate, the analyst notes.</p><p><blockquote>分析师指出，由于利伦替利单抗的表现比安慰剂差，因此显然存在疑问，为什么II期的干净结果没有转化。</blockquote></p><p> Cowen analyst Joseph Thome has also cut the recommendation on Allakos to Market Perform from Outperform without the price target (PT) pending pipeline clarity.</p><p><blockquote>Cowen分析师Joseph Thome也将Allakos的评级从跑赢大盘下调至大盘表现，但价格目标(PT)有待管道明确。</blockquote></p><p> SVB Leerink analyst Thomas Smith downgraded the stock to Market Perform from Outperform, with PT of $17.</p><p><blockquote>SVB Leerink分析师Thomas Smith将该股评级从跑赢大盘下调至与大盘持平，PT为17美元。</blockquote></p><p> Barclays analyst Carter Gould lowered the firm's PT on Allakos to $8 from $36 and keeps an Underweight rating. The company's lead asset failed in key Phase 3 studies, Gould tells investors in a research note. He views this as the \"end game\" for lirentelimab.</p><p><blockquote>Barclays分析师Carter Gould将该公司对Allakos的PT从36美元下调至8美元，并维持跑输大盘评级。古尔德在一份研究报告中告诉投资者，该公司的主要资产在关键的第三阶段研究中失败了。他认为这是利伦替利单抗的“终结游戏”。</blockquote></p><p> Morgan Stanley says Allakos' disappointing data increase&nbsp;eosinophilic gastrointestinal diseases (EGIDs) uncertainty.</p><p><blockquote>摩根士丹利表示，Allakos令人失望的数据增加了嗜酸性胃肠道疾病（EGIDs）的不确定性。</blockquote></p><p> Jefferies analyst Maury Raycroft cut the recommendation on&nbsp;Allakos&nbsp;to Hold from Buy.</p><p><blockquote>杰富瑞(Jefferies)分析师莫里·雷克罗夫特(Maury Raycroft)将Allakos的评级从买入下调至持有。</blockquote></p><p> LifeSci Capital analyst Samuel Slutsky downgraded the stock to Market Perform from Outperform.</p><p><blockquote>LifeSci Capital分析师Samuel Slutsky将该股评级从跑赢大盘下调至与大盘持平。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ALLK":"Allakos Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1163953446","content_text":"Allakos continues to slide, falls 87.4% premarket following yesterday's announcement that its late-stage studies, KRYPTOS and ENIGMA 2failed to achieve statistical significance.\n\nThe studies met their histologic co-primary endpoints but failed to achieve symptomatic endpoints.\nIn ENIGMA, patients treated with lirentelimab achieved a 10.0-point reduction in Total Symptom Score-6 (TSS-6) at weeks 23-24 from baseline (baseline = 29.5) compared to an 11.5-point reduction in the placebo group (baseline = 27.7; p=0.343).\nOn the second co-primary endpoint of absolute mean change in patient reported Dysphagia Symptom Questionnaire in KRYPTOS trial, the high-dose group achieved a 17.4-point reduction, the low-dose group achieved an 11.9-point reduction and placebo achieved a 14.6-point reduction.\nFollowing this disappointing result, several analysts lowered their ratings of the stock and slashed the price targets.\nWilliam Blair downgraded the stock to Market Perform from Outperform.\nAnalysts of the firm say, \"while we believe lirentelimab has shown clear evidence of histologic activity against eosinophils and mast cells, the failure to achieve co-primary endpoints of patient reported symptoms in both studies raises questions about whether these histologic improvements can translate into clinical improvements.\"\nWith lirentelimab performing worse than placebo, there are clearly questions as to why the clean results in Phase II didn’t translate, the analyst notes.\nCowen analyst Joseph Thome has also cut the recommendation on Allakos to Market Perform from Outperform without the price target (PT) pending pipeline clarity.\nSVB Leerink analyst Thomas Smith downgraded the stock to Market Perform from Outperform, with PT of $17.\nBarclays analyst Carter Gould lowered the firm's PT on Allakos to $8 from $36 and keeps an Underweight rating. The company's lead asset failed in key Phase 3 studies, Gould tells investors in a research note. He views this as the \"end game\" for lirentelimab.\nMorgan Stanley says Allakos' disappointing data increase eosinophilic gastrointestinal diseases (EGIDs) uncertainty.\nJefferies analyst Maury Raycroft cut the recommendation on Allakos to Hold from Buy.\nLifeSci Capital analyst Samuel Slutsky downgraded the stock to Market Perform from Outperform.","news_type":1,"symbols_score_info":{"ALLK":0.9}},"isVote":1,"tweetType":1,"viewCount":3057,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":605846773,"gmtCreate":1639148160346,"gmtModify":1639148161911,"author":{"id":"4098850726603110","authorId":"4098850726603110","name":"nick name","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4098850726603110","authorIdStr":"4098850726603110"},"themes":[],"htmlText":"reason ?","listText":"reason ?","text":"reason ?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/605846773","repostId":"1159401236","repostType":2,"isVote":1,"tweetType":1,"viewCount":2816,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"defaultTab":"following","isTTM":false}